adamantane has been researched along with Chronic Illness in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boulton, DW; Pfister, M; Zhang, L | 1 |
| Barbieri, M; Campitiello, F; Canonico, R; Canonico, S; Carbonara, O; Della Corte, A; Ferraraccio, F; Gualdiero, P; Marfella, R; Padovano, V; Paolisso, G; Paolisso, P; Petrella, A; Petronella, P; Rizzo, MR; Sasso, FC | 1 |
| Campestrini, J; Dilzer, SC; Dole, WP; He, YL; Howard, D; Lasseter, KC; Ligueros-Saylan, M; Sabo, R; Wang, Y | 1 |
| Rekalova, EM | 1 |
| Belshe, R; Berry, C; De Grazia, F; Lin, A; Milazzo, J; Tomlinsin, D; Wells, S; Wills, RJ | 1 |
2 trial(s) available for adamantane and Chronic Illness
| Article | Year |
|---|---|
Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Capillaries; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Foot; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gene Expression Regulation; Glucagon-Like Peptide 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Italy; Male; Middle Aged; Neovascularization, Physiologic; Nitriles; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrrolidines; RNA, Messenger; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Vildagliptin; Wound Healing | 2012 |
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
Topics: Adamantane; Adult; Analysis of Variance; Area Under Curve; Chronic Disease; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Liver Diseases; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
3 other study(ies) available for adamantane and Chronic Illness
| Article | Year |
|---|---|
A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
Topics: Adamantane; Chronic Disease; Computer Simulation; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Kidney Diseases; Models, Biological; Renal Dialysis | 2012 |
[The immunomodulator kemantan in the treatment of patients with exacerbated chronic obstructive bronchitis].
Topics: Adamantane; Adult; Bronchitis; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Immunity, Cellular; Male; Respiratory Insufficiency | 1992 |
Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease.
Topics: Adamantane; Adult; Aged; Chronic Disease; Female; Half-Life; Humans; Liver Diseases; Male; Middle Aged; Rimantadine | 1987 |